Endocrine Abstracts

Therapeutic interferon-β (IFN-β) preparations have been approved for treatment for multiple sclerosis (MS). However, the development of neutralising antibodies (NAbs) against IFN-β in MS patients reduces therapeutic efficacy. Early detection of NAbs is critical for the modification of treatment regimes. IFN-β exerts its biological effects by binding to receptors on target cells and stimulating the expression of IFN-β-inducible genes. Measurement of end...